Patents by Inventor Michelle Mader

Michelle Mader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220390463
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: July 28, 2022
    Publication date: December 8, 2022
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Robert ARCH, Jun ZHANG, Michelle MADER, Tetsuya ISHINO, Joel BARD, William FINLAY, Orla CUNNINGHAM, Ciara REILLY, Peter BRAMS, Brigitte DEVAUX, Haichun HUANG, Karla HENNING
  • Patent number: 11474112
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 18, 2022
    Assignees: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
  • Publication number: 20190331694
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: May 24, 2019
    Publication date: October 31, 2019
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
  • Publication number: 20190048073
    Abstract: The present invention provides for anti-GD3 antibodies, and ADCs and methods for preparing and using the same.
    Type: Application
    Filed: July 19, 2018
    Publication date: February 14, 2019
    Inventors: Faical Miyara, Dhanvanthri S Deevi, Lioudmila Tchistiakov, Michelle Mader, Yijie Gao, Paul Chapman, Govind Ragupathi
  • Publication number: 20180052175
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: May 22, 2017
    Publication date: February 22, 2018
    Inventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning